Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Drugs in development: bisphosphonates and metalloproteinase inhibitors. | Arthritis Research and Therapy Vol 5 No 1 Catterall and Cawston Review Drugs in development bisphosphonates and metalloproteinase inhibitors Jon B Catterall and Tim E Cawston Department of Rheumatology The Medical School University of Newcastle upon Tyne UK Corresponding author Tim E Cawston e-mail T.E.Cawston@ncl.ac.uk Received 16 July 2002 Revisions received 13 September 2002 Accepted 23 September 2002 Published 8 November 2002 Arthritis Res Ther 2003 5 12-24 DOI 10.1186 ar604 2003 BioMed Central Ltd Print ISSN 1478-6354 Online ISSN 1478-6362 Abstract The destruction of bone and cartilage is characteristic of the progression of musculoskeletal diseases. The present review discusses the developments made with two different classes of drugs the bisphosphonates and matrix metalloproteinase inhibitors. Bisphosphonates have proven to be an effective and safe treatment for the prevention of bone loss especially in osteoporotic disease and may have a role in the treatment of arthritic diseases. The development of matrix metalloproteinase inhibitors and their role as potential therapies are also discussed especially in the light of the disappointing human trials data so far published. Keywords bone cartilage collagen metalloproteinases tissue inhibitor of metalloproteinase Introduction Structural damage to the joint is characteristic of both rheumatoid arthritis RA and osteoarthritis OA . It is a predictor of long-term outcome and it contributes over time to functional decline disability and major surgical procedures. Protecting bone and articular cartilage from damage consequently has major potential both therapeutically and economically. It has been estimated that approximately 25 of disability in RA can be explained by progressive joint damage after the first 5-10 years 1 . If joint destruction can be prevented or significantly reduced then the long-term function of joints could be preserved severe disability could be avoided and patients would benefit from a much .
